Cardlytics, Inc. (NASDAQ:CDLX) CEO Lynne Marie Laube sold 2,139 shares of the stock in a transaction dated Tuesday, April 13th. The stock was sold at an average price of $105.44, for a total value of $225,536.16. Following the completion of the sale, the chief executive officer now owns 319,306 shares of the company’s stock, valued at $33,667,624.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Lynne Marie Laube also recently made the following trade(s):
- On Wednesday, March 24th, Lynne Marie Laube sold 4,278 shares of Cardlytics stock. The stock was sold at an average price of $122.52, for a total transaction of $524,140.56.
- On Wednesday, February 10th, Lynne Marie Laube sold 2,139 shares of Cardlytics stock. The stock was sold at an average price of $153.03, for a total value of $327,331.17.
Shares of CDLX opened at $124.03 on Friday. Cardlytics, Inc. has a fifty-two week low of $38.00 and a fifty-two week high of $161.47. The company has a 50 day moving average price of $122.30 and a 200-day moving average price of $118.93. The company has a debt-to-equity ratio of 1.14, a quick ratio of 6.08 and a current ratio of 6.08. The stock has a market capitalization of $3.94 billion, a PE ratio of -73.83 and a beta of 2.63.
CDLX has been the topic of several recent research reports. Truist raised their target price on shares of Cardlytics from $90.00 to $150.00 in a report on Monday, March 1st. William Blair lowered shares of Cardlytics from an “outperform” rating to a “market perform” rating in a report on Thursday, January 14th. They noted that the move was a valuation call. Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “buy” rating and set a $145.00 price objective on the stock in a report on Wednesday. Bank of America raised shares of Cardlytics from an “underperform” rating to a “neutral” rating and set a $128.00 target price for the company in a research report on Thursday, March 11th. Finally, Wells Fargo & Company raised shares of Cardlytics from an “equal weight” rating to an “overweight” rating and set a $150.00 price objective for the company in a research report on Thursday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $129.67.
Several large investors have recently bought and sold shares of the company. Marshall Wace LLP acquired a new position in Cardlytics during the first quarter worth approximately $336,000. FMR LLC boosted its stake in Cardlytics by 2.3% during the 1st quarter. FMR LLC now owns 3,284,572 shares of the company’s stock valued at $54,327,000 after acquiring an additional 72,847 shares during the last quarter. UBS Asset Management Americas Inc. lifted its position in shares of Cardlytics by 3.3% in the 3rd quarter. UBS Asset Management Americas Inc. now owns 22,414 shares of the company’s stock worth $1,582,000 after buying an additional 722 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Cardlytics by 17.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 175,838 shares of the company’s stock worth $12,409,000 after buying an additional 26,572 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Cardlytics in the 3rd quarter worth about $356,000. 97.03% of the stock is owned by institutional investors and hedge funds.
Cardlytics, Inc engages in the development of marketing solutions through its purchase intelligence platform. It operates through the Cardlytics Direct and Other Platform Solutions segments. The Cardlytics Direct segment represents its proprietary native bank advertising channel. The Other Platform Solutions segment includes solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel.
Further Reading: Dividend Reinvestment Plan (DRIP)
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.